SCHEMBL2306473

SCHEMBL2306473

Clc1cccc(Cl)c1CN1CCNCC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A13 Q16696 2/20 0.62
SIGMAR1 Q99720 1/20 0.58
KDM4E B2RXH2 2/20 0.57
ALDH1A1 P00352 2/20 0.57
ADRB1 P08588 2/20 0.53
DRD2 P14416 1/20 0.53
DRD3 P35462 1/20 0.53
CXCR4 P61073 6/20 0.50
SLC6A2 P23975 1/20 0.50
SLC6A4 P31645 1/20 0.50
SLC6A3 Q01959 1/20 0.50
MEN1 O00255 1/20 0.49
CHRM2 P08172 1/20 0.49
CHRM1 P11229 1/20 0.49
ADRA2C P18825 1/20 0.49
CCR2 P41597 1/20 0.49
CXCL12 P48061 1/20 0.49
BLM P54132 1/20 0.49
KMT2A Q03164 1/20 0.49
TDP1 Q9NUW8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7426972 0.98 CYP2A13 (0.61) CYP2A13SIGMAR1KDM4EALDH1A1ADRB1
Hydrochloric Acid SCHEMBL7429845 0.92 CXCR4 (0.61) CYP2A13SIGMAR1KDM4EALDH1A1ADRB1
SCHEMBL209940 0.88 CYP2A13 (0.68) CYP2A13SIGMAR1KDM4EALDH1A1MEN1
Hydrochloric Acid SCHEMBL7429353 0.87 CYP2A13 (0.66) CYP2A13SIGMAR1KDM4EALDH1A1MEN1
SCHEMBL15094606 0.84 DRD2 (0.58) CYP2A13SIGMAR1KDM4EALDH1A1ADRB1
SCHEMBL3968896 0.84 KDM4E (0.70) CYP2A13SIGMAR1KDM4EALDH1A1ADRB1
SCHEMBL2010728 0.83 CYP2A13 (0.61) CYP2A13KDM4EALDH1A1CXCR4MEN1
SCHEMBL15093763 0.81 CYP2A13 (0.61) CYP2A13SIGMAR1KDM4EALDH1A1ADRB1
SCHEMBL30596550 0.80 KDM4E (0.70) CYP2A13KDM4EALDH1A1MEN1KMT2A
SCHEMBL538314 0.79 SIGMAR1 (0.66) CYP2A13SIGMAR1KDM4EALDH1A1ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104046246-B The chemical-mechanical planarization of tungsten-containing substrate 气体产品与化学公司 2016-06-15 CN claimed
US-20140273458-A1 Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-18 US claimed
EP-2779217-A2 Chemical mechanical planarization for tungsten-containing substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-17 EP claimed
CN-104046246-A Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PROD & CHEM 2014-09-17 CN claimed
EP-2006271-A9 SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2009-07-29 EP claimed
US-20090054401-A1 Substituted bicyclic derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-02-26 US claimed
EP-2006271-A2 SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2008-12-24 EP claimed
CN-113214275-B Pyranocarbazole alkaloid derivative and application thereof in treating nervous system diseases 中国医学科学院药物研究所 2023-09-26 CN disclosed
EP-4008717-A2 NOVEL INHIBITORS OF INSULIN-LIKE GROWTH FACTOR 2 MRNA BINDING PROTEINS Martin-Luther-Universität Halle-Wittenberg (DE) 2022-06-08 EP disclosed
EP-4008716-A1 NOVEL INHIBITORS OF INSULIN-LIKE GROWTH FACTOR 2 MRNA BINDING PROTEINS Martin-Luther-Universität Halle-Wittenberg (DE) 2022-06-08 EP disclosed
CN-113214275-A Pyranocarbazole alkaloid derivatives and their use for treating nervous system diseases 中国医学科学院药物研究所 2021-08-06 CN disclosed
EP-3310778-B1 KOJIC ACID-DERIVED MANNICH BASES WITH BIOLOGICAL EFFECT AYTEMIR MUTLU (TR) 2019-07-17 EP disclosed
US-9975884-B2 Kojic acid-derived mannich bases with biological effect AYTEMIR MUTLU (TR) 2018-05-22 US disclosed
WO-2006069805-A2 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT 4 AZA IP NV (BE) 2006-07-06 WO disclosed
EP-1673092-A1 HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY 4 AZA Bioscience nv (BE) 2006-06-28 EP disclosed
WO-2005039587-A1 HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY 4 AZA BIOSCIENCE NV (BE) 2005-05-06 WO disclosed
US-5219857-A Method of treating cognitive and related neural behavioral problems AMERICAN CYANAMID COMPANY (US) 1993-06-15 US disclosed
US-5126340-A Antidepressants AMERICAN CYANAMID COMPANY (US) 1992-06-30 US disclosed
US-4963553-A TREATING COGNITIVE AND NEURAL BEHAVIORAL PROBLEMS IN MAMMALS AMERICAN CYANAMID CO. (US) 1990-10-16 US disclosed
EP-0264773-A1 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidines AMERICAN CYANAMID COMPANY (US) 1988-04-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054401-A1 Substituted bicyclic derivatives and use thereof LTB4R2, LTC4S, LTB4R CYP2A13 274/4885SIGMAR1 480/4885KDM4E 2981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.